Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Methods of treating cancers using bis(thiohydrazide amide) compounds


Stanford Reference:

11-265


Abstract


Researchers in Dr. James Ford’s lab have developed methods of using bis(thiohydrazide amide) compounds to treat patients with DNA-repair compromised cancers. Many cancers are aggressive and have high rates of relapse following chemotherapy. Among such cancers is the basal-like breast cancer subtype which includes hereditary breast cancers due to germline mutations in BRCA1. These cancers tend to be relatively insensitive to existing “targeted” therapeutics and thus additional treatment options are necessary. To help provide new treatment options the inventors took advantage of their recent finding that these cancers have an impaired ability to repair oxidative DNA damage and thus the cancers are selectively sensitive to bis(thiohydrazide amide) compounds that produce elevated levels of oxidative DNA damage. This technology provides methods to treat patients that have aggressive DNA repair-compromised cancers.

Stage of research
Using in vitro cellular assays, the inventors have shown that a bis(thiohydrazide amide) compound, induced cell death in up to 75% of basal-like breast cancer cells and in up to 95% of BRCA1-mutated breast cancer cells. Normal breast cells and luminal breast cancer cells remained unaffected. Thus bis(thiohydrazide amide) compounds may be a useful therapeutic option for DNA-repair compromised cancers.



Applications


  • Cancer therapeutic for DNA-repair compromised cancers including:
    • Basal-like sporadic breast cancers
    • BRCA1-mutated hereditary breast cancers
    • Triple-negative breast cancer

Advantages


  • DNA-repair compromised cancers are selectively sensitive to bis(thiohydrazide amide) compounds
    • Maximize therapeutic benefit
    • Minimize unnecessary side effects
  • Bis(thiohydrazide amide) compounds may be used in combination therapies

Publications



Related Web Links



Innovators & Portfolio



Date Released

 8/26/2014
 

Licensing Contact


Mary Albertson, Senior Licensing Associate
(650) 725-9411 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
00-252 Isozyme-selective PKC Inhibitors and Activators
01-246 Agents to inhibit pathological angiogenesis

more technologies »

Related Keywords


therapeutic: anticancer   molecular biomarkers cancer   prognostic markers   DNA repair   cancer drug therapy   cancer combination therapy   breast cancer   biomarker: cancer   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
00-252 Isozyme-selective PKC Inhibitors and Activators
01-246 Agents to inhibit pathological angiogenesis

Recently Viewed...
S11-265 Methods of treating cancers using bis(thiohydrazide amide) compounds